Lineage Therap Expands ATM Equity Offering Capacity

Lineage Therap ( (LCTX) ) has provided an announcement.

On March 11, 2026, Lineage Cell Therapeutics, Inc. filed a new prospectus supplement with the U.S. Securities and Exchange Commission to update its existing shelf registration, enabling ongoing at-the-market offerings of common shares through B. Riley Securities, Inc. Under this arrangement, the company may sell up to an additional $60 million of common shares, on top of roughly $22.6 million previously sold, expanding its capacity to raise equity capital over time and potentially strengthening its financial flexibility for operations and growth initiatives.

The most recent analyst rating on (LCTX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.

Spark’s Take on LCTX Stock

According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.

The score is held back primarily by weak financial performance driven by heavy losses and ongoing cash burn, despite low leverage. Offsetting this, the latest earnings call highlighted an extended funding runway and meaningful operational milestones, and technicals are supportive with price above major moving averages. Valuation remains constrained by lack of profitability and no dividend support.

To see Spark’s full report on LCTX stock, click here.

More about Lineage Therap

Lineage Cell Therapeutics, Inc. is a biotechnology company operating in the U.S. life sciences sector, focused on developing and commercializing cell-based therapies. Its primary activities center on advancing therapeutic candidates and accessing capital markets to fund research, development, and potential commercialization efforts.

Average Trading Volume: 1,180,423

Technical Sentiment Signal: Buy

Current Market Cap: $450.8M

Find detailed analytics on LCTX stock on TipRanks’ Stock Analysis page.